The effect of chitosan supplementation on changes of body weight, glycemic risk factors (fasting glucose, insulin, glycated hemoglobin), lipid profile and visceral adiposity index in patients with nonalcoholic fatty liver disease (NAFLD)

Ahvaz University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新: 2018年6月18日

适应症

试验速览

暂无简介。

•Individuals of both genders (males and females) will be selected to participate in the study, aged between 18 and 65 years old that their fatty liver diagnosed by ultrasound testing
•No allergies to seafood

•Hepatitis, liver cirrhosis, Wilson's disease, acute fatty liver, pregnancy, hepatocellular carcinoma, hypothyroidism and chronic liver disease
•Lipodystrophy
•Parenteral nutrition
•Diseases that involve bile ducts and bile ducts
•Severe weight loss (more than 10% of body weight) during last 6 months and weight loss surgery
•Congenital metabolic diseases
•Consumption of Herbal Supplements in the last three months
•Taking drugs that cause fatty liver and liver toxicity (amiodarone, antivirals, spirin, non-steroidal anti-inflammatory drugs, corticosteroids, methotrexate, tamoxifen, tetracycline, valproic acid
•Pregnancy and lactation
•Consumption of Omega 3 and Vitamin E and other antioxidant supplements over the past 6 months
•History of cardiovascular disease and kidney disease
•BMI between 25 and 40
•Unwillingness to participate
•Energy consumption less than 800 or more than 4200kcal/day

发起方